Program
apatinib
Also written as “Apatinib”, “Rivoceranib” and “Apatinib Mesylate”.
Its studies are mostly in Stomach Neoplasms · Ovarian Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Carcinoma, Non-Small-Cell Lung, led by 8 companies.
Drug pageApatinib: every studyMany companies study it; this page follows only the 47 they lead. All 428 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 344 open or running | phase 3since Jan 13, 2012 | Aug 30, 2010 | none ahead |
| Elevar Therapeuticsits history only | 70 open or running | phase 3since Jan 24, 2017 | Dec 18, 2011 | none ahead |
| Bukwang Pharmaceuticalits history only | 10 open or running | phase 1since Feb 26, 2016 | Feb 26, 2016 | none ahead |
| GrandPharma (China)its history only | 11 open or running | phase 2since Aug 13, 2025 | Aug 13, 2025 | Dec 30, 2027phase 2 · NCT07334483 |
| Guangzhou Virotech Pharmaceuticalits history only | 11 open or running | phase 3since May 8, 2026 | May 8, 2026 | Dec 31, 2028phase 3 · NCT07589244 |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since Jan 7, 2025 | Jan 7, 2025 | none ahead |
| HRYZ Biotechits history only | 11 open or running | early phase 1since Aug 26, 2019 | Aug 26, 2019 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 2since Aug 14, 2017 | Aug 14, 2017 | none ahead |
Also a collaborator on its studies: Bukwang Pharmaceutical.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Jiangsu HengRui Medicine only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Aug 30, 2010.
- Dec 13, 2019Phase 3 study in PD-L1 Positive Non-small Cell Lung CancerNCT04203485 · 762 enrolled
- Jan 12, 2020Phase 3 study in Ovarian NeoplasmsNCT04229615 · 690 enrolled · China
- Mar 3, 20202 phase 3 studiesNCT04296370, NCT04335006
- Mar 17, 2020Phase 1 study in Advanced Solid TumorNCT04322552 · 18 enrolled · China
- Apr 8, 2020Phase 1 study in Healthy SubjectsNCT04341090 · 42 enrolled · China
- Apr 9, 2020Phase 3 study in Stomach NeoplasmsNCT04342910 · 550 planned · China
- May 6, 2020Phase 2 study in Ovarian NeoplasmsNCT04383977 · 54 enrolled
- May 13, 2020Phase 1 study in NSCLCNCT04390984 · 22 enrolled · China
- Jun 1, 20202 phase 1 studiesNCT04414852, NCT04457180
- Aug 16, 2020Phase 2 study in Ovarian NeoplasmsNCT04517357 · 100 enrolled · China
- Nov 19, 2020Phase 3 study in Carcinoma, HepatocellularNCT04639180 · 687 enrolled · China
- Apr 26, 2021Phase 2 study in Metastatic Castration Resistant Prostate CancerNCT04869488 · 93 enrolled · China
- Jul 15, 2021Phase 3 study in Advanced Hepatocellular Carcinoma (HCC)NCT04985136 · 1 enrolled · China
- Apr 2, 2022Phase 3 study in Carcinoma, HepatocellularNCT05320692 · 423 enrolled · China
TargetBeta
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 34 Jiangsu HengRui Medicine leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05320692Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jul 30, 2026 | 423 |
| NCT04985136Advanced Hepatocellular Carcinoma (HCC) · China | 3 | Terminated | Dec 29, 2021 | 1 |
| NCT04869488Metastatic Castration Resistant Prostate Cancer · China | 2 | Completed | Feb 14, 2023 | 93 |
| NCT04639180Carcinoma, Hepatocellular · China | 3 | Active, not recruiting | Jul 31, 2026 | 687 |
| NCT04517357Ovarian Neoplasms · China | 2 | Completed | Nov 30, 2023 | 100 |
| NCT04457180Advanced Solid Tumor · China | 1 | Completed | May 20, 2021 | 18 |
| NCT04414852Subjects With Impaired Renal Function and Healthy Subjects | 1 | UNKNOWN | Jan 15, 2021 | 24 |
| NCT04390984NSCLC · China | 1 | UNKNOWN | Feb 2021 | 22 |
| NCT04383977Ovarian Neoplasms | 2 | UNKNOWN | Dec 2020 | 54 |
| NCT04342910Stomach Neoplasms · China | 3 | Recruiting | Apr 1, 2026 | 550 |
| NCT04341090Healthy Subjects · China | 1 | Completed | Jul 6, 2020 | 42 |
| NCT04335006Breast Neoplasms · China | 3 | Terminated | Apr 14, 2023 | 80 |
| NCT04322552Advanced Solid Tumor · China | 1 | Completed | Apr 3, 2021 | 18 |
| NCT04296370Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation · China | 3 | Recruiting | Jun 30, 2022 | 474 |
| NCT04229615Ovarian Neoplasms · China | 3 | UNKNOWN | Jun 30, 2023 | 690 |
| NCT04203485PD-L1 Positive Non-small Cell Lung Cancer | 3 | UNKNOWN | Mar 31, 2022 | 762 |
| NCT04000295Ovarian Neoplasms · China | 3 | UNKNOWN | Jan 2021 | 280 |
| NCT03945604Triple Negative Breast Neoplasms · China | 1 | Completed | Feb 9, 2021 | 32 |
| NCT03711279Sarcoma · China | 2 | Terminated | Jun 21, 2021 | 99 |
| NCT03491631Neoplasms · China | 1 | UNKNOWN | Jun 2023 | 23 |
| NCT03472365Stomach Neoplasms · China | 2 | Completed | Nov 25, 2020 | 67 |
| NCT03463876Carcinoma, Hepatocellular · China | 2 | Completed | Mar 10, 2021 | 190 |
| NCT03245307Cytochrome P450 Interaction · China | 1 | UNKNOWN | Apr 30, 2018 | 20 |
| NCT03075462Ovarian Neoplasms · China | 1 | Completed | Aug 22, 2021 | 98 |
| NCT03026881Recurrence · China | 1 | UNKNOWN | Apr 2018 | 24 |
| NCT02836171Neoplasms · China | 1 | Completed | Feb 2017 | 20 |
| NCT02836821Neoplasms · China | 1 | Completed | Feb 2017 | 20 |
| NCT02764268Stomach Neoplasms · China | – | Completed | Dec 10, 2018 | 60 |
| NCT02332512Carcinoma, Non-Small-Cell Lung · China | 3 | UNKNOWN | Aug 2017 | 417 |
| NCT02329860Carcinoma, Hepatocellular · China | 3 | Completed | Dec 15, 2017 | 400 |
| NCT01531777Colorectal Neoplasms · China | 2 | Completed | Nov 2014 | 40 |
| NCT01512745Stomach Neoplasms · China | 3 | Completed | May 2013 | 267 |
| NCT01270386Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Jul 2011 | 136 |
| NCT01192971Neoplasms · China | 2 | Completed | Jul 2013 | 121 |
How it is read
Names in the registry
- “Apatinib”, 13 entries
- “Rivoceranib”, 5 entries
- “Apatinib Mesylate”, 5 entries
- “apatinib”, 3 entries
- “Fluzoparib+Apatinib”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 8 studies
- Ovarian Neoplasms, 6 studies
- Neoplasms, 6 studies
- Carcinoma, Hepatocellular, 5 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.